Pfizer (PFE) Short-Term Debt repayments (2016 - 2025)
Historic Short-Term Debt repayments for Pfizer (PFE) over the last 13 years, with Q2 2025 value amounting to $151.0 million.
- Pfizer's Short-Term Debt repayments fell 9666.22% to $151.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $10.0 billion, marking a year-over-year decrease of 2103.1%. This contributed to the annual value of $11.2 billion for FY2024, which is 37410000.0% up from last year.
- As of Q2 2025, Pfizer's Short-Term Debt repayments stood at $151.0 million, which was down 9666.22% from $2.0 billion recorded in Q1 2025.
- In the past 5 years, Pfizer's Short-Term Debt repayments registered a high of $7.8 billion during Q3 2024, and its lowest value of $1.0 million during Q4 2021.
- In the last 5 years, Pfizer's Short-Term Debt repayments had a median value of $1.2 billion in 2024 and averaged $2.3 billion.
- As far as peak fluctuations go, Pfizer's Short-Term Debt repayments crashed by 9999.43% in 2021, and later soared by 38860000.0% in 2022.
- Quarter analysis of 5 years shows Pfizer's Short-Term Debt repayments stood at $1.0 million in 2021, then surged by 388600.0% to $3.9 billion in 2022, then tumbled by 99.92% to $3.0 million in 2023, then skyrocketed by 259033.33% to $7.8 billion in 2024, then tumbled by 98.06% to $151.0 million in 2025.
- Its last three reported values are $151.0 million in Q2 2025, $2.0 billion for Q1 2025, and $7.8 billion during Q3 2024.